DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
IPO Year:
Exchange: NYSE
Website: davita.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/6/2024 | $133.00 | Equal Weight | Barclays |
| 8/7/2023 | $100.00 → $142.00 | Neutral → Buy | UBS |
| 11/1/2022 | $97.00 → $72.00 | Buy → Hold | Deutsche Bank |
| 10/31/2022 | $117.00 → $74.00 | Buy → Neutral | UBS |
| 8/19/2022 | $106.00 → $117.00 | Buy | UBS |
| 6/21/2022 | $110.00 → $90.00 | Underperform | BofA Securities |
| 1/5/2022 | $114.00 → $125.00 | Hold | Truist Securities |
| 10/29/2021 | $113.00 → $111.00 | Sector Perform | RBC Capital |
| 10/13/2021 | $145.00 → $125.00 | Hold | Truist Securities |
| 9/10/2021 | $145.00 | Market Perform | Cowen & Co. |
DENVER, April 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Monday, May 12, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the
DENVER, March 6, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at the Barclays Global Healthcare Conference 2025 on Tuesday, March 11, 2025, at 9:00 a.m. EDT. To view the live webcast, visit the Barclays page and create a free registration. About DaVita Inc. DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares fo
CHICAGO and DENVER, Feb. 27, 2025 (GLOBE NEWSWIRE) -- YMCA of the USA (Y-USA), the national resource office for the 2,600+ YMCAs across the country, is excited to expand its collaboration with DaVita, a leading provider of comprehensive kidney care, to advance chronic disease education and prevention for individuals and their families who are either managing or at risk for chronic kidney disease (CKD). CKD disproportionately affects individuals with risk factors such as hypertension and diabetes. Following an investment from the DaVita Giving Foundation, Y-USA and DaVita will collaborate to further close the kidney health education gap, empower early risk detection and connect individuals
DENVER, Feb. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended December 31, 2024. "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range," said Javier Rodriquez, CEO of DaVita Inc. "As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita, we look forward to continuing our efforts to improve clinical outcomes, enhance quality of life for our patients and teammates, and be a force for positive change in the healthcare system." Financial and operating highlights for the quarter and year ended Decembe
DENVER, Jan. 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 13, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Thursday, February 13, 2025Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to
DENVER, Jan. 15, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care provider, is celebrating 25 years of clinical care delivery and leadership in healthcare innovation. Since forming with a purpose "to give life" in 2000, DaVita has focused its efforts to improve clinical outcomes, enhance quality of life for patients and be a force for positive change for the healthcare system. By fostering an inclusive, mission-driven workforce and building strong community partnerships, DaVita is helping empower the future of kidney health. DaVita's 25 years of clinical excellence is built on a steadfast commitment to patient-centered care — through purpose-driven clinical strategy, value-based prog
LOS ANGELES, Jan. 9, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care provider, has activated its emergency response plan as devastating wildfires spread across Southern California. DaVita's emergency response plan includes: Accounting for patients and teammates (employees), assessing facilities in the affected areas and identifying safe shelters.Transferring patients to centers that can safely provide dialysis treatment.Providing patients with relevant medical information—including prescription, dietary instructions and fluid restrictions—should they need to dialyze at a different center.Coordinating with other dialysis and health care providers to help ensure continuity of care for
DENVER, Nov. 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at UBS Global Healthcare Conference 2024 on Tuesday, November 12, 2024 at 12:30 pm PST (3:30 pm EST). To view the live webcast, visit the UBS page here and create a free registration. About DaVita Inc. DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 20 years.
DENVER, Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of our patients and our frontline caregivers." Financial and operating highlights for the quarter ended September 30, 2024: Consolidated revenues were $3.264 billion.Operating income was $535 million.Diluted earnings per share was $2.50 and adjusted diluted earnings per share was $2.
The program aims to bring together a supportive network for people dealing with chronic health challenges for themselves and their loved ones DENVER, Oct. 28, 2024 /PRNewswire/ -- The DaVita Giving Foundation today announced an investment in the National Kidney Foundation (NKF)'s PEERS program, a program that provides social and emotional support for patients, care partners, and living donors through connections with mentors living through similar experiences. Prioritizing mental health in chronic disease care is essential, and mentorship can help provide people with support and comfort in a time when they might otherwise feel alone. Studies1 show that social connection can help reduce the r
SC 13G/A - DAVITA INC. (0000927066) (Subject)
SC 13G/A - DAVITA INC. (0000927066) (Subject)
SC 13D/A - DAVITA INC. (0000927066) (Subject)
SC 13D/A - DAVITA INC. (0000927066) (Subject)
SC 13G/A - DAVITA INC. (0000927066) (Subject)
DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C
DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on
Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),
Award celebrates excellence in nursing, underscoring the kidney care provider's commitment to recognizing the indelible impact of clinicians on outstanding patient care DENVER, May 9, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that 54 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week. The award is part of The DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 6,500 health care facilities nationwide. "Nurses are such
DENVER, April 10, 2024 /PRNewswire/ -- DaVita Inc. today announced that its Board of Directors has appointed a new independent director, Dennis Pullin, to join the Board, effective April 10, 2024. "We're pleased to welcome Dennis to DaVita's board," said Pamela Arway, independent chair of the DaVita Inc. Board of Directors. "Given his depth of experience within the healthcare system, we're excited about the perspective Dennis will bring to the Board and look forward to his positive impact on our future growth and performance." Mr. Pullin is a recognized thought leader and advo
DENVER, July 13, 2023 /PRNewswire/ -- DaVita Inc. today announced that its Board of Directors appointed a new independent director, Wendy Schoppert, to join the Board, effective as of July 14, 2023. "We're pleased to welcome Wendy to DaVita's board," said Pam Arway, independent chair of the DaVita Inc. Board of Directors. "Her proven track record and broad corporate and board expertise will positively impact our governance and strategy." Ms. Schoppert has more than 30 years of leadership experience, including serving as Executive Vice President and Chief Financial Officer of S
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar
Group Believes Board Has Disregarded Shareholders' Concerns by Appointing Solomon Trujillo as "Independent" Chairman Highlights Conflicting Financial Arrangements and Interlocks Among Board Members, Including Mr. Trujillo and Chief Executive Officer Marlow Hernandez Reiterates Demand that the Board Respect the Wishes of Shareholders by Making Necessary Leadership Changes or Reopening the Window to Nominate Director Candidates and Submit Proposals at 2023 Annual Meeting Elliot Cooperstone, Lewis Gold and Barry Sternlicht (collectively with certain of their affiliates, the "Group" or "we"), who recently resigned as members of the Board of Directors (the "Board") of Cano Health, Inc. ("C
DENVER, Sept. 13, 2022 /PRNewswire/ -- DaVita Inc. announced today that its Board of Directors appointed a new independent director, Adam H. Schechter, to join the Board, effective September 20, 2022. Mr. Schechter is the President, Chief Executive Officer and Chair of the Board of Directors of Laboratory Corporation of America Holdings ("Labcorp"), a leading global life sciences company with $16.1 billion in reported revenues in 2021. Mr. Schechter has served as President and CEO of LabCorp since November 2019, as a director since April 2013 and as Chair of the Board since M
DENVER, April 7, 2022 /PRNewswire/ -- DaVita Inc. announced today that its board of directors appointed a new independent director, Jason M. Hollar, to join the board, effective May 6, 2022. Mr. Hollar brings more than 25 years of financial experience spanning the health care, transportation, manufacturing and retail sectors to the board. Mr. Hollar currently serves as chief financial officer of Cardinal Health, Inc., a globally integrated health care services and products company with over $160 billion in 2021 revenues. Mr. Hollar leads financial activities across the Cardina
DENVER, April 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Monday, May 12, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the
DENVER, Feb. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended December 31, 2024. "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range," said Javier Rodriquez, CEO of DaVita Inc. "As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita, we look forward to continuing our efforts to improve clinical outcomes, enhance quality of life for our patients and teammates, and be a force for positive change in the healthcare system." Financial and operating highlights for the quarter and year ended Decembe
DENVER, Jan. 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 13, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Thursday, February 13, 2025Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to
DENVER, Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of our patients and our frontline caregivers." Financial and operating highlights for the quarter ended September 30, 2024: Consolidated revenues were $3.264 billion.Operating income was $535 million.Diluted earnings per share was $2.50 and adjusted diluted earnings per share was $2.
DENVER, Oct. 9, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Tuesday, October 29, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, October 29, 2024Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen
DENVER, Aug. 6, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended June 30, 2024. "On behalf of all the teammates who provide life-saving care to our patients, I am grateful for the opportunity to report another positive quarter for DaVita," said Javier Rodriguez, CEO of DaVita Inc. "We continue to enhance our clinical capabilities while optimizing our revenue operations and cost structure." Financial and operating highlights for the quarter ended June 30, 2024: Consolidated revenues were $3.187 billion.Operating income was $506 million.Diluted earnings per share was $2.50 and adjusted diluted earnings per share was $2.59.Operating cas
DENVER, July 18, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 6, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, August 6, 2024Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen t
DENVER, May 2, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2024. "Through the first quarter, we continued building on the momentum generated through 2023, demonstrating operational discipline while continuing to find opportunities to invest, innovate and most importantly deliver clinical excellence," said Javier Rodriguez, CEO of DaVita Inc. Financial and operating highlights for the quarter ended March 31, 2024: Consolidated revenues were $3.071 billion.Operating income was $484 million and adjusted operating income was $463 million.Diluted earnings per share was $2.65 and adjusted diluted earnings per share was $2.38
DENVER, April 17, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 2, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Thursday, May 2, 2024Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to th
DENVER, Feb. 13, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2023. "As we reflect on the past year, our 2023 financial performance highlighted the resilience of our business," said Javier Rodriguez, CEO of DaVita Inc. "The external challenges of recent years ultimately made us stronger, and with continued investment in our teammates, systems, and capabilities, we believe that we are well positioned for the years ahead. We enter 2024 with more confidence than we have had since the start of COVID in 2020." Financial and operating highlights for the quarter and year ended December 31, 2023: Consolidated revenu
Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00
UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously
Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously
UBS downgraded DaVita from Buy to Neutral and set a new price target of $74.00 from $117.00 previously
UBS resumed coverage of DaVita with a rating of Buy and set a new price target of $117.00 from $106.00 previously
BofA Securities reiterated coverage of DaVita with a rating of Underperform and set a new price target of $90.00 from $110.00 previously
Truist Securities reiterated coverage of DaVita with a rating of Hold and set a new price target of $125.00 from $114.00 previously
RBC Capital reiterated coverage of DaVita with a rating of Sector Perform and set a new price target of $111.00 from $113.00 previously
Truist Securities reiterated coverage of DaVita with a rating of Hold and set a new price target of $125.00 from $145.00 previously
Cowen & Co. initiated coverage of DaVita with a rating of Market Perform and set a new price target of $145.00
DEFA14A - DAVITA INC. (0000927066) (Filer)
DEF 14A - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
10-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
10-Q - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
8-K - DAVITA INC. (0000927066) (Filer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)